AMO Pharma, a British biopharmaceutical company, is targeting a pathway most often associated with cancer to treat people with genetic encephalopathy (GE).
https://www.pharmalive.com/wp-content/uploads/2020/05/AMO-Drug-May-Restore-Normal-Learning-Function-in-Some-Genetic-Brain-Diseases-BioSpace-5-8-10.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-05-08 11:54:172020-05-08 11:54:57AMO Drug May Restore Normal Learning Function in Some Genetic Brain Diseases